[IL-6 targeting therapy to retard structural joint damage in patients with rheumatoid arthritis].
Tocilizumab has been shown to have strong effect to retard the progression of structural joint damage in patients with rheumatoid arthritis. It was approved not only for signs and symptoms but also structural joint damage of rheumatoid arthritis in Japan. In this review, the efficacy, utility, positioning, and the future prospect will be discussed.
Nishimoto
Norihiro
N
Laboratory of Immune Regulation, Wakayama Medical University.
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000209:etiology*; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D006801:Humans; D015850:Interleukin-6 / Q000502:physiology; D019947:Receptors, Interleukin-6 / Q000276:immunology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015850:Interleukin-6; D019947:Receptors, Interleukin-6; C502936:tocilizumab